Immunotherapy, including programmed cell death protein‐1 and programmed death ligand‐1 (PD‐1/PD‐L1) blockade, has been demonstrated to inhibit cancer progression and validated with the clinical success for the treatment of a variety of human cancers.111. This evidence concerns the gene CD274 and cancer.